Table 1 |
|||
|
Small molecule MEK1/2 inhibitors in clinical trials |
|||
|
Inhibitor |
Company |
Phase |
Status |
|
|
|||
|
CI-1040 |
Pfizer |
Phase II |
Development stopped |
|
PD0325901 |
Pfizer |
Phase I/II |
Development stopped |
|
AZD6244 |
Array BioPharma/ AstraZeneca |
Phase II |
In progress |
|
GDC-0973 |
Exelixis/ Genentech |
Phase I |
In progress |
|
RDEA119 |
Ardea Biosciences/ Bayer |
Phase I/II |
In progress |
|
GSK1120212 |
GlaxoSmithKline |
Phase I/II |
In progress |
|
AZD8330 |
Array BioPharma/ AstraZeneca |
Phase I |
In progress |
|
RO5126766 |
Hoffmann La Roche |
Phase I |
In progress |
|
RO4987655 |
Hoffmann La Roche |
Phase I |
In progress |
|
TAK-733 |
Millenium Pharmaceuticals |
Phase I |
In progress |
|
AS703026 |
EMD Serono |
Phase I |
In progress |
|
|
|||
|
Frémin and Meloche Journal of Hematology & Oncology 2010 3:8 doi:10.1186/1756-8722-3-8 |
|||
